What is BioKier?
BioKier operates at the intersection of biotechnology and metabolic medicine, specializing in the development of oral products that mimic the physiological benefits of bariatric-metabolic surgery. By targeting gut hormone secretion and the regulation of glucose and lipids, the company provides a non-invasive alternative for patients struggling with metabolic syndrome. Their clinical-stage status is bolstered by successful trial data, positioning BioKier as a disruptive force in the diabetes management sector. The company leverages a collaborative network of scientific experts to refine its therapeutic candidates, ensuring that its clinical development strategy remains aligned with rigorous medical standards and patient outcomes.
How much funding has BioKier raised?
BioKier has raised a total of $34K across 1 funding round:
Debt
$34K
Debt (2021): $34K with participation from PPP
Key Investors in BioKier
PPP
Public-Private Partnership
What's next for BioKier?
With the recent infusion of capital, BioKier is well-positioned to advance its lead candidates through the next phases of clinical validation. The strategic roadmap likely involves scaling manufacturing capabilities and expanding trial sites to support broader regulatory submissions. As the company matures, the focus will shift toward commercialization readiness and potential strategic partnerships with larger pharmaceutical entities. By maintaining its commitment to mimicking surgical metabolic outcomes through oral delivery, BioKier is poised to capture significant market share in the rapidly evolving landscape of metabolic disease therapeutics, ultimately aiming to improve long-term cardiometabolic health for a global patient population.
See full BioKier company page
